文献速递消化道肿瘤放疗放疗物理与技术

18F-FDG PET/CT引导的局部晚期食管癌放疗剂量递增I期研究

18F-FDG PET/CT directed radiotherapy dose escalation in locally advanced esophageal cancer (LAEC), a phase I study.
PubMed 文献 · Radiother Oncol · 2025-09-28

这项I期研究评估局部晚期食管癌患者接受50 Gy同步放化疗后,对PET/CT定义的残留代谢病灶进行超分割推量放疗的最大耐受剂量。21例可评估患者中,推量至36 Gy(总剂量86 Gy,BED 100.32 Gy)可安全联合每周紫杉醇/卡铂,未达到MTD,常见急性≥3级毒性为食管炎17%和中性粒细胞减少24%。

要点

  • 50 Gy同步放化疗后PET/CT残留代谢病灶行超分割推量至36 Gy安全可行。
  • 总复合肿瘤剂量86 Gy(BED 100.32 Gy)联合每周紫杉醇/卡铂未达MTD。
  • 常见急性≥3级毒性为食管炎17%和中性粒细胞减少24%。

核心结论

  • 36 Gy超分割推量至PET/CT定义的残留代谢病灶,总剂量86 Gy(BED 100.32 Gy),可安全联合每周紫杉醇/卡铂同步给药。
  • 最大耐受剂量(MTD)尚未确定。

研究设计与样本

  • I期剂量递增研究,采用改良Fibonacci设计。
  • 21例局部晚期食管癌患者可评估。
  • 患者接受每周紫杉醇/卡铂同步放化疗(SCRT)联合图像引导调强放疗(IG-IMRT),残留代谢病灶者接受超分割推量同步化疗。

主要发现

  • 4例达到完全代谢缓解(CMR)。
  • 剂量限制性毒性(DLT)发生在28.8 Gy和36 Gy。
  • 常见急性≥3级毒性为食管炎(17%)和中性粒细胞减少(24%)。
  • 晚期毒性包括1-2级食管狭窄(n=5)。
  • 总缓解率为88%;中位随访9个月,仅1例发生局部区域失败。

关键数值与推荐

  • DLT定义为≥4级食管炎、≥3级非血液学毒性(除恶心/呕吐外)或持续>7天的≥4级血液学毒性。
  • MTD定义为DLT发生率≤1例患者的最高剂量。

临床怎么用

  • 对局部晚期食管癌患者,50 Gy同步放化疗后PET/CT显示残留代谢病灶者,可考虑超分割推量至36 Gy联合每周紫杉醇/卡铂。
  • 需关注急性≥3级食管炎和中性粒细胞减少,以及晚期食管狭窄。

局限性

  • MTD未达到,需进一步确定。
  • 样本量小(21例),随访时间短(中位9个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To determine the maximum tolerated dose (MTD) of hyperfractionated radiotherapy (HFRT) boost for residual metabolic disease (RMD) as defined by PET/CT following SCRT with concurrent paclitaxel (P) and carboplatin (C) for locally advanced esophageal cancer (LAEC). MATERIALS AND METHODS: Eligible patients received standard chemoradiation therapy(SCRT) with weekly paclitaxel and carboplatin plus preirradiation PET/CT-guided intensity-modulated radiotherapy (IG-IMRT). Patients with RMD received HFRT boost concurrent with the same chemotherapy. Boost doses were escalated using a modified Fibonacci design. Dose limiting toxicity (DLT) was defined as grade ≥4 esophagitis, grade ≥3 non-hematological toxicity (except nausea/vomiting), or grade ≥4 hematological toxicity lasting >7 days. MTD was the highest dose with ≤1 pts experiencing DLT. RESULTS: 21pts were assessable. SCRT was well-tolerated. 4 pts achieved complete metabolic response (CMR). DLT occurred at 28.8 and 36 Gy. The MTD wasn't reached. The most common acute grade ≥ 3 toxicities were esophagitis (17 %), neutropenia (24 %). Late toxicity included grade 1 or 2 esophageal stricture (n = 5). Overall response rate was 88 %. With median follow-up of 9 months, local-regional failure only occurred in 1pt. CONCLUSION: 36 Gy HFRT boost to PET/CT-defined RMD after 50 Gy SCRT using IG-IMRT, resulting in a total composite tumor dose of 86 Gy (BED 100.32 Gy), can be safely delivered concurrent with weekly P/C. MTD remains to be defined.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Cheng N, Chen Z, Chen Y, et al. 18F-FDG PET/CT directed radiotherapy dose escalation in locally advanced esophageal cancer (LAEC), a phase I study. Radiother Oncol. 2025. PMID: 41027512. doi:10.1016/j.radonc.2025.111176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。